Evidence map›Paper›PMID 37351232›Full record

ReviewCureus2023

The Prevalence and Incidence of Hemolytic Uremic Syndrome: A Systematic Review.

Sarah S Aldharman, Shahad M Almutairi, Alaa A Alharbi, Meshal A Alyousef, Khalid H Alzankrany, Mohammed K Althagafi, Emtenan E Alshalahi, Khalid H Al-Jabr, Abdullrahman Alghamdi, Syed F Jamil

Abstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Shiga toxin-producingMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah S AldharmanCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Shahad M AlmutairiCollage of Medicine, King Saud University, Riyadh, SAU.
Alaa A AlharbiDepartment of Psychiatry, King Salman Bin Abdulaziz Medical City, Medina, SAU.
Meshal A AlyousefCollege of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, SAU.
Khalid H AlzankranyCollege of Medicine, Alrayan Medical College, Medina, SAU.
Mohammed K AlthagafiCollege of Medicine, King Abdulaziz University, Jeddah, SAU.
Emtenan E AlshalahiCollege of Medicine, Qassim University, Al-Qassim, SAU.
Khalid H Al-JabrCollege of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, SAU.
Abdullrahman AlghamdiCollege of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, SAU.
Syed F JamilCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hemolytic uremic syndrome is an uncommon but severe condition brought on by an overactive alternative complement system, typically involving a hereditary component. It will be crucial to comprehend the epidemiology of hemolytic uremic syndrome as research advances toward bettering its diagnosis and treatment. A systematic review was conducted to evaluate the incidence and prevalence estimates of hemolytic uremic syndrome (HUS) internationally. A thorough literature search was conducted using PubMed, Springer, Cochrane Library for Systematic Reviews, and Embase databases between 2012 and 2023 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations. A further source of data was the PubMed Central search engine. To make sure that the evaluation included just the studies that were the most pertinent, a population, interventions, comparators, and outcomes (PICO) eligibility criterion was also used. Eight articles were included in this review. HUS had an annual crude incidence of 0.66 per 100,000 people and a standard annual incidence of 0.57 per 100,000 people. Females were more likely than males to develop HUS, but only marginally more frequently. Patients under 20 years old were the age group where HUS was most common. HUS had an average cost of $21,500 per patient, which was more expensive than the country's overall inpatient average cost for the same period. This is due to patients requiring supportive care, antibiotics, plasma exchange, plasma infusion, and renal replacement therapy, and it could take multiple courses of treatment before they improve. It was concluded that several variables, including the region, the age group affected, and the frequency of the underlying bacterial infection, determine the prevalence and incidence of HUS. HUS is often more common in children than adults and is more common in some nations. Overall, HUS is an uncommon disorder that can have significant repercussions for people who have it. For better results and fewer consequences, HUS must be diagnosed and treated as soon as possible.

Indexed as

hemolytic uremic syndromeincidenceprevalencerenal impairmentsystematic review

Identifiers

PMID37351232
PMCPMC10284565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.